CD274 and neoplasm: Patients with PD-L1 tumor area positivity ≥5% who had received 1–2 prior chemotherapy regimens (including at least one platinum-based) were randomized in a 3:1 ratio to receive atezolizumab 1,200 mg with or without Tiragolumab 600 mg every 3 weeks until disease progression or unacceptable toxicity.